Ex Vivo AI seeks to transform early stage drug discovery by automating small molecule synthesis and reaction optimization. Through the development of state-of-the-art AI techniques, we enable the rapid production of desired compounds with less time and fewer materials in a way that seamlessly integrates with existing experimental practices.